The UK-listed pharma’s shares fell 7% on reports of a Bristol Myers Squibb merger. A $380 bln deal would muddy CEO Pascal Soriot’s growth pitch without yielding fat returns. Given US expansion is doable organically, the plan may go the way of Pfizer’s 2014 swoop on Astra itself.
